premature newborns without NEC

PreclinicalBiologic

premature newborns without NEC is one of 18 biologic programs targeting Necrotizing Enterocolitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Necrotizing EnterocolitisActive, not recruiting

Necrotizing EnterocolitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Necrotizing Enterocolitis

#DrugCompanyPhaseTrials

N-Acetyl Cyteien

SStanford University

Approved

1 2

Trental

VValidus Pharmaceuticals

Phase 3

1 3

Lumason

BBracco Diagnostics, Inc

Phase 3

1 4

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 3

1 5

Saccharomyces Boulardii

BBiocodex

Phase 3

1 6

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 1

2 7

Cafcit

KKaken Pharmaceutical

Phase 1

1 8

Amikin

IInsmed Incorporated

Phase 1

1 9

ST266

NNoveome Biotherapeutics, formerly Stemnion

Phase 2

1 10

IBP-9414

IInfant Bacterial Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Necrotizing Enterocolitis1 trial

Cohort of Premature Newborns for Charaterization of the Digestive Microbiota in Ulcerative Necrotizing Enterocolitis in Premature Infants

Completed·UUniversity Hospital, Clermont-Ferrand·Preclinical·NCT04972734·297 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for premature newborns without NEC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — premature newborns without NEC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for premature newborns without NEC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Clermont-Ferrand

premature newborns without NEC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Necrotizing Enterocolitis1 trial

References

Drug Info

Quick Facts

Related News